Disclosures

Hanna Zimmermann received research grants from Novartis.

Judith Bellmann-Strobl has received travel grants and speaking fees from Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi-Aventis/Genzyme, Teva Pharmaceuticals unrelated to this study.

Friedemann Paul  reports research grants and speaker honoraria from Bayer,
Teva, Genzyme, Merck, Novartis, MedImmune and is a member of the steering
committee of the OCTIMS study (Novartis), all unrelated to this work.

Alexander U. Brandt is the founder and holds shares of Motognosis and Nocturne. He is named as an inventor on several patent applications describing serum biomarkers for MS, perceptive visual computing for tracking of motor dysfunction and OCT image
analysis.